LakeShore Biopharma Co. (LSB) - רווח נקי למניה (EPS TTM)

Automated plants in China with autonomous power supplies served as the foundation for LakeShore Biopharma (LSB) growth. The current annual net income per unit confirms this resilience, while the value of 0.00 captures the metric level. Stable cash flow ensures leadership in the anti-rabies drug segment, while the aggressive commercialization of new vaccines based on proprietary adjuvants expands the company's production capacities.

The indicator is calculated by dividing the total annual net income by the total number of outstanding securities. This metric determines the actual earnings per share, which is critical when assessing business valuation. For LakeShore Biopharma Co. (LSB), such data reflects the efficiency of patent capitalization and compliance with GMP standards. High barriers to entry in the vaccine sector make this income more stable. By analyzing the trailing twelve-month earnings per share, an investor can identify the capital accumulation phase prior to a trend reversal.